Clinical Course Of Disease In Participants With FA-CM
← catalyst calendarNCT06865482 · readout ≤ 407 d
Sponsored by Lexeo Therapeutics (industry) · LXEO — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
65estimated
Sites
19
Countries
Brazil, Canada, Czechia +5
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-09-30 | actual | When the study began enrolling |
| Primary completion | Sep 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Sep 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2025-03-07 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-08 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Friedreich Ataxia
- Cardiomyopathy
Primary outcome
what the primary-completion date above is the date OFCharacterize cardiac disease presentation and progression among participants
measured 26 weeks
Permalink · LXEO's whole pipeline · Catalyst calendar · Every registered study · What changed